Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Invested Capital (2016 - 2025)

Historic Invested Capital for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $194.5 million.

  • Zevra Therapeutics' Invested Capital rose 17873.73% to $194.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $194.5 million, marking a year-over-year increase of 17873.73%. This contributed to the annual value of $99.2 million for FY2024, which is 39.57% down from last year.
  • Zevra Therapeutics' Invested Capital amounted to $194.5 million in Q3 2025, which was up 17873.73% from $177.9 million recorded in Q2 2025.
  • Zevra Therapeutics' Invested Capital's 5-year high stood at $439.6 million during Q2 2023, with a 5-year trough of $32.5 million in Q2 2024.
  • Over the past 5 years, Zevra Therapeutics' median Invested Capital value was $127.1 million (recorded in 2021), while the average stood at $187.0 million.
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 9261.19% in 2024, then skyrocketed by 44782.31% in 2025.
  • Over the past 5 years, Zevra Therapeutics' Invested Capital (Quarter) stood at $127.1 million in 2021, then tumbled by 40.91% to $75.1 million in 2022, then surged by 32.54% to $99.6 million in 2023, then dropped by 0.4% to $99.2 million in 2024, then skyrocketed by 96.1% to $194.5 million in 2025.
  • Its Invested Capital was $194.5 million in Q3 2025, compared to $177.9 million in Q2 2025 and $41.0 million in Q1 2025.